GASTROINTESTINAL INFECTIONS: Edited by Mark H. WilcoxComparison of the 2010 and 2017 Infectious Diseases Society of America guidelines on the diagnosis and treatment of Clostridium difficile infectionWilcox, Mark H.; Rooney, Christopher M.Author Information Microbiology, Leeds Teaching Hospitals NHS Trust & University of Leeds, Leeds, UK Correspondence to Professor Mark H. Wilcox, Microbiology, Old Medical School, Leeds General Infirmary, Leeds LS1 3EX, West Yorkshire, UK. Tel: +44 113 392 6818; fax: +44 113 392 2696; e-mail: [email protected] Current Opinion in Gastroenterology: January 2019 - Volume 35 - Issue 1 - p 20-24 doi: 10.1097/MOG.0000000000000489 Buy Metrics Abstract Purpose of review To highlights the key changes in the updated Infectious Diseases Society of America and Society for Healthcare Epidemiology of America guidelines with respect to the diagnosis and treatment of Clostridium difficile infection (CDI). Recent findings CDI continues as a major threat to healthcare institutions and as a community-associated infection related primarily to antibiotic exposure. Infectious Diseases Society of America/Society for Healthcare Epidemiology of America produced extensive CDI guidelines in 2010; in 2018, updated guidance has been published. The new guidelines include key changes with respect to the treatment and diagnosis of CDI. Summary Updated, evidence guidelines allow optimization of the diagnosis of CDI and the use of therapeutic interventions, in particular to reduce the risk of recurrent infection. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.